News

Enlarge image

ResearchEUBelgiumUK

Diving for novel antibiotics

15.02.2013 - The EU-project PharmaSea will bring researchers to some of the deepest, coldest and hottest places on the planet in the hunt for novel antibiotics.

Scientists from the UK, Belgium, Norway, Spain, Ireland, Germany, Italy, Switzerland and Denmark will work together to collect and screen samples of mud and sediment from huge, previously untapped, oceanic trenches. The large-scale, four-year project is backed by more than €9.5 million of EU funding and brings together 24 partners from 14 countries from industry, academia and non-profit organisations.

The PharmaSea project focuses on biodiscovery research and the development and commercialisation of new bioactive compounds from marine organisms, including deep-sea sponges and bacteria, to evaluate their potential as novel drug leads or ingredients for nutrition or cosmetic applications. The international team of scientists is led by Professor Marcel Jaspars of the University of Aberdeen in Scotland, and coordinated by Dr. Camila Esguerra of the University of Leuven in Belgium.

Only a handful of samples have ever been taken from deep trenches and investigated, so the project is breaking new ground. "PharmaSea will not only be exploring new territory at the bottom of the oceans, but also new areas in ‘chemical space’. With our broad platform of cutting-edge bioassays to detect drug-like activity, we'll be testing many unique chemical compounds from these marine samples that have literally never seen the light of day. We're quite hopeful that we'll find a number of exciting new drug leads", says Dr. Camila Esguerra, Industrial Research Fellow and Lecturer with the Laboratory for Molecular Biodiscovery at the University of Leuven.

The international team will employ strategies commonly used in the salvage industry to carry out the sampling. Using fishing vessels, researchers will drop a sampler on a reel of cables to the trench bed to collect sediment. Scientists will then attempt to grow unique bacteria and fungi from the sediment that can be extracted to isolate novel drug-like molecules for pharmacological testing. Partners from China, Chile, Costa Rica, New Zealand and South Africa will support the PharmaSea project. The first field tests will be carried out next autumn in the Atacama Trench in the Eastern Pacific Ocean, about 100 miles off the coast of Chile and Peru. The team will also search the Arctic waters off Norway and the Antarctic via Italian and South African partners. Deep trenches will also be accessed off New Zealand and China.

Marine organisms that live more than 6,000 meters below the sea level are considered to be an interesting source of novel bioactive compounds as they survive under extreme conditions. "Trenches are separated from each other and represent islands of diversity. They are not connected to each other and life has evolved differently in each one", explains Marcel Jaspars. 

© eurobiotechnews.eu/al

http://www.european-biotechnology-news.com/news/news/2013-01/plunging-new-depths-for-novel-antibiotics.html

CommercialisationEU

10.02.2016 In future, meds will come in packages sporting a unique barcode and an anti-tampering device. These measures are part of the EU’s new regulation to safeguard against falsified medicines.

Clinical ResearchFrancePortugalEU

05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.

M&ASwitzerland

04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.

FinancingEUUKBelgium

01.02.2016 Newly formed Medicxi Ventures, a life sciences-dedicated VC firm based in London, Geneva and Jersey, has closed a €210m investment fund to reinvest in European early-stage assets.

ResearchUKEU

01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.

M&ASwedenIceland

28.01.2016 Swedish infectious disease specialist Enzymatica has bagged Icelandic company Zymetech, who produces the patent-protected enzyme used in Enzymatica’s own common cold blocker ColdZyme.

R&DUK

27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.

Clinical TrialsGermany

25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.

AMREU

21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.

M&AFinland

19.01.2016 Biotie Therapies has long been expanding its business in the US. Now, the Finnish company is set to be taken over by US company Acorda Therapeutics, which is paying €321m for the shares.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS (CH)0.05 CHF25.00%
  • ZEALAND PHARMA (DK)105.50 DKK14.05%
  • SARTORIUS (D)244.45 EUR12.88%

FLOP

  • PAION (D)1.25 EUR-36.55%
  • SWEDISH ORPHAN BIOVITRUM (S)12.45 USD-23.38%
  • BIOTIE THERAPEUTICS (FI)0.14 EUR-22.22%

TOP

  • VERONA PHARMA (UK)3.30 GBP24.5%
  • IXICO (UK)35.75 GBP21.2%
  • SAREUM HOLDINGS (UK)0.30 GBP15.4%

FLOP

  • BIONOR PHARMA (N)0.81 NOK-52.9%
  • PAION (D)1.25 EUR-48.6%
  • CYTOS (CH)0.25 CHF-34.2%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)24.50 SEK3081.8%
  • NICOX (F)6.80 EUR245.2%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)8.65 SEK-85.8%
  • BIOTEST (D)13.40 EUR-85.5%
  • EVOCUTIS (UK)0.08 GBP-71.4%

No liability assumed, Date: 10.02.2016